Document is current

Any future updates will be listed below

Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up

Crossref DOI link: https://doi.org/10.1007/s00432-016-2334-x

Published Online: 2017-01-12

Published Print: 2017-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark